HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer

This is a Phase I/II, single-arm, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HSK42360-Na tablets combined with cetuximab with or without chemotherapy in patients with BRAF V600-mutant metastatic colorectal cancer (mCRC). The Phase I stage uses a 3+3 dose escalation design to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of HSK42360-Na in combination with cetuximab. The Phase II stage evaluates the efficacy and safety of HSK42360-Na combined with cetuximab alone or with mFOLFOX6/FOLFIRI che

Trial Details

NCT ID
NCT07790510
Phase
PHASE1 / PHASE2
Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Status
RECRUITING
Cancer Type
Rectal Cancer Colorectal Cancer
Interventions
  • HSK42360-Na Tablets
  • Cetuximab (EGFR inhibitor)
  • mFOLFOX6 Regimen (Oxaliplatin/Leucovorin/5-FU)
  • FOLFIRI Regimen (Irinotecan/Leucovorin/5-FU)
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Age ≥18 years; voluntarily participate in this clinical trial, understand the study procedures, and have signed the informed consent form;
  • ECOG performance status 0-1;
  • Estimated survival time \>3 months;
  • Histologically or cytologically confirmed metastatic and unresectable colorectal adenocarcinoma. For Phase I, Phase II Cohort 1, and the safety lea…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Rectal Cancer Colorectal Cancer Trials on Trialify →